Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders

 Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders

Sage Therapeutics’ Zulresso (brexanolone) Receives FDA’s Approval for Postpartum Depression (PPD)

Shots:

  • The P-III MOUNTAIN study involves assessing of SAGE-217 (20/ 30mg) vs PBO in 581 patients with MDD
  • The P-III MOUNTAIN study results: did not meet its 1EP i.e, reduction in 17-item HAM-D score @15days; SAGE-217 (30mg) showed mean reduction in HAM-D (12.6 vs 11.2); reduction in HAM-D@3, 8 &12days; safe & well tolerated. Patients showed significant improvement in previous studies i.e, (HAM-D>24)
  • SAGE-217 (PO) is a neuroactive steroid (NAS) GABAA receptor positive allosteric modulator, being evaluated in 5 studies out of which two reported positive data in MDD and PPD

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post